Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

February 25, 2023

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
ADHD
Interventions
DRUG

NRCT-101-SR

NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.

DRUG

Placebo

Matching placebo

Trial Locations (9)

29405

Coastal Carolina Research Center - North Charleston, North Charleston

32751

Accel Research Sites, Maitland

33176

Miami Dade Medical Research Institute, Miami

33803

Accel Research Sites, Lakeland

82642

Velocity Clinical Research - Meridian, Meridian

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

92845

Collaborative Neuroscience Network, Garden Grove

02131

Alcanza Clinical Research Company, Boston

08009

Hassman Research Institute, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neurocentria, Inc.

INDUSTRY

NCT05683249 - Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter